Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States-Reference-Cited by-同舟云学术

Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States

Published:2009-10 Issue:4 Volume:53 Page:642-646
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Mvundura Mercy,Amendah Djesika,Kavanagh Patricia L.,Sprinz Philippa G.,Grosse Scott D.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference20 articles.

1. Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals, 2004. In HCUP statistical brief #21. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf. Accessed January 17, 2008.

2. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment;Steinberg;JAMA,2003

3. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial;Gaston;N Engl J Med,1986

4. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002;Yanni;J Pediatr,2009

5. Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGE review;Ashley-Koch;Am J Epidemiol,2000

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costs and impact of disease in adults with sickle cell disease: a pilot study;Blood Advances;2024-07-10

2. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease;PLOS ONE;2024-06-25

3. National Quality Indicators in Pediatric Sickle Cell Anemia;Pediatrics;2024-03-06

4. A feasibility randomized controlled trial of an mHealth app vs booklets for patient-facing guidelines in adults with SCD;Blood Advances;2023-10-13

5. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States;Advances in Therapy;2023-06-18